---
title: "Varegacestat (AL102) in Desmoid tumors: Expected outcomes of therapy"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Expected outcomes of therapy. Topics: Treatment goals in guidelines and health technology assessment, Company-stated treatment goals for varegacestat, Expected tumor control with varegacestat in RINGSIDE Part B, Expected symptom relief with varegacestat in RINGSIDE Part B, and 5 further topics. 10 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

- Treatment of progressing desmoid tumors aims to control tumor growth and relieve symptoms. NICE describes it as “non-curative and aims to control tumour growth and alleviate symptoms”, the 2023 consensus update calls for selecting each patient's management strategy to optimize tumor control and enhance quality of life, and Immunome states that treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function.
- Tumor control with varegacestat in RINGSIDE Part B (data cutoff October 7, 2025): PFS of 94% at 1 year and 89% at 2 years with varegacestat, compared with 66% and 57% with placebo; a hazard ratio of 0.16 (95% CI 0.071, 0.375) and a confirmed objective response rate of 56% versus 9% in Immunome's ESMO release; and a median time to response of 8.2 months among varegacestat responders.
- Symptom outcomes in RINGSIDE Part B: Immunome reports a worst pain difference of more than 2 points from the first evaluation at week 4. At week 48, least-squares mean changes were -1.50 with varegacestat and +0.59 with placebo on the GODDESS TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
- Treatment duration: median exposure in RINGSIDE Part B was 20.3 months with varegacestat as of October 7, 2025, and median time on treatment in RINGSIDE phase 2 as of April 10, 2024 was 23.1 months in one abstract and 25.4 months in another. Immunome anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Pauses and retreatment: in the NICE appraisal of nirogacestat, clinical experts supported stopping after 2 years if treatment could continue while the tumor was still shrinking or restart if it grew again. The company reported that less than 1% of people in its compassionate use programme continued beyond year 2, and the committee assumed that most patients stop after 2 years. The long-term nirogacestat follow-up publication (Ratan et al. 2025) states that optimal duration and responses after discontinuation are not well defined. The Desmoid Tumor Working Group states that shrinkage can continue after withdrawal, that long-term disease control is achieved in up to 50–70% of patients, and that treatment can be repeated at recurrence.
- Long-term continuous nirogacestat: in long-term follow-up of participants randomly assigned to nirogacestat, the objective response rate was 34.3%, 41.4%, 44.3%, and 45.7% with up to 1, 2, 3, and 4 years of treatment, with no additional progression or death events after year 2. In the French DeNi real-world study, median treatment duration was 16 months, the 1-year PFS rate was 76.2%, and 38 of 49 participants with baseline pain (78%) reported pain improvement.

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/); [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/); [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/); [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-2.2.2.7-2"></a>

### Treatment goals in guidelines and health technology assessment

> “It is imperative to carefully select the management strategy for each patient with DT to optimize tumor control and enhance quality of life.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

> “In this setting, treatment is non-curative and aims to control tumour growth and alleviate symptoms rather than address the underlying cause of the disease.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

> “Usual treatment for progressing desmoid tumours that need systemic treatment is non-curative and aims to manage symptoms.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

> “The goals, she said, are clear:”
> “to shrink the tumor, reduce pain, and improve mobility.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

<a id="topic-2.2.2.7-3"></a>

### Company-stated treatment goals for varegacestat

> “For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-2.2.2.7-4"></a>

### Expected tumor control with varegacestat in RINGSIDE Part B

| Arm | Progression-free at 1 year | Progression-free at 2 years |
| --- | --- | --- |
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

> “The confirmed objective response rate (ORR) based on RECIST v1.1 was 56% with varegacestat vs. 9% with placebo (p<0.0001), as assessed by blinded independent central review.”
> “Varegacestat improved progression-free survival (PFS) vs. placebo, with an 84% reduction in the risk of disease progression or death (hazard ratio [HR] = 0.16, 95% confidence interval [CI]: 0.071, 0.375; p<0.0001).”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

> “Among responders treated with varegacestat, median time to response was 8.2 months (range: 2.6-28.0 months) vs. 16.7 months (range: 8.1-30.2 months) for responders receiving placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-2.2.2.7-5"></a>

### Expected symptom relief with varegacestat in RINGSIDE Part B

> “A clinically significant difference of more than 2 points was observed as early as the first evaluation at week 4.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

> “At week 48, patients treated with varegacestat had a least-squares mean change from baseline in the GODDESS TSS-5 symptom score of -1.50 vs. +0.59 for patients receiving placebo, with lower scores indicating lower symptom burden. On the PROMIS Physical Function measure, where higher scores indicate better function, the least-squares mean change from baseline was +3.90 with varegacestat vs. -3.04 with placebo at week 48.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-2.2.2.7-6"></a>

### Treatment duration in RINGSIDE

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “RINGSIDE Phase 2 enrolled 42 participants, of whom 29 (69%) entered the OLE. As of April 10, 2024, median time on treatment was 23.1 months (range 0.7 – 26.6) and 23 participants (55%) were still on treatment.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-2.2.2.7-7"></a>

### Treatment duration, pauses, and retreatment with gamma secretase inhibitors

> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “The EAG noted that clinical experts broadly supported stopping treatment after 2 years. But it added that this was only if there was flexibility to continue for longer if the tumour was still shrinking, or restart if, for example, the tumour started growing again.”
> “The company provided data on tumour size plateaus. It said that by year 2, 100% of tumours had plateaued in people with complete and partial response. In people with stable disease, more than 75% of tumours had plateaued.”
> “It recalled that retreatment with nirogacestat was not permitted in De-Fi, so the trial did not provide evidence on restarting treatment after stopping.”
> “The company highlighted that based on data from its compassionate use programme (up to April 2025), less than 1% of people having nirogacestat continue treatment beyond year 2.”
> “They explained that people in their practice usually stop nirogacestat after about 1 year, very few would continue beyond year 2 and the number of people needing retreatment is low.”
> “So, the committee concluded that while it would not recommend a stopping rule, the model should assume that most patients stop treatment after 2 years to align with clinical practice, with a proportion of people continuing or restarting treatment.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

> “Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined. In the setting of limited data, decisions on treatment duration, discontinuation, and rechallenge with nirogacestat are best made in collaboration between patients and their treating clinicians.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

> “Shrinkage can continue even after treatment withdrawal, and long-term disease control is usually achieved in up to 50–70% of the patients depending on the series. Of note, at recurrence, and especially if the patients responded to the therapy, the treatment can be repeated with substantial benefit.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.7-8"></a>

### Long-term outcomes with continuous gamma secretase inhibitor treatment

> “No additional events (progression or death) occurred with additional exposure after year 2”
> “The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.”
> “For patients continuing treatment after the first year, the incidence and severity of frequently reported TEAEs decreased through subsequent years.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

> “All patients who achieved a PR continue to maintain responses between 47.9 and 73+ months. Four patients stopped treatment yet remain free of progression between 11 and 53+ months.”

Source: [Villalobos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28887726/)

<a id="topic-2.2.2.7-9"></a>

### Real-world outcomes with nirogacestat

> “The estimated median duration of nirogacestat treatment was 16 months. Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions. Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.”

Source: [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)

> “Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in magnetic resonance imaging (MRI) T2-weighted signal intensity. Nine out of 10 patients who presented with pain (90%) reported rapid improvement.”

Source: [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)

<a id="topic-2.2.2.7-10"></a>

### Reduced need for supportive procedures in intra-abdominal disease

> “The clinical expert also explained that people with desmoid tumours, particularly intra-abdominal tumours, may need stomas, ureteric stents and home intravenous nutrition. The need for these may be reduced if nirogacestat was available.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
